Bristol-Myers Squibb is a one of the leading global specialty biopharmaceutical companies focused on the development of treatments targeting serious diseases like cancer, inflammatory, immunologic, cardiovascular or fibrotic diseases. Backed by its blockbuster immuno-oncology drug, Opdivo, Bristol-Myers has a strong oncology portfolio, comprising other drugs like Revlimid, Pomalyst, Sprycel, Yervoy and Empliciti. It also has important immunology and cardiovascular drugs like Orencia and Eliquis. It's experiencing growth in both the Eliquis brand and the market, while also advancing its Factor XIa inhibitor program. After the sale of the global Diabetes business to AstraZeneca and the discontinuation of discovery research efforts in virology, it's focusing solely on research in core therapeutic areas like oncology, immuno-oncology, immunoscience, cardiovascular, fibrosis and genetically defined diseases. It acquried Celgene Corporation and MyoKardia. It received regulatory approvals for Reblozyl and Inrebic.
| Revenue (Most Recent Fiscal Year) | $45.01B |
| Net Income (Most Recent Fiscal Year) | $8.03B |
| PE Ratio (Current Year Earnings Estimate) | 75.30 |
| PE Ratio (Trailing 12 Months) | 42.43 |
| PEG Ratio (Long Term Growth Estimate) | 15.06 |
| Price to Sales Ratio (Trailing 12 Months) | 1.98 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 5.46 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | 3.57 |
| Pre-Tax Margin (Trailing 12 Months) | -12.84% |
| Net Margin (Trailing 12 Months) | -13.50% |
| Return on Equity (Trailing 12 Months) | 8.83% |
| Return on Assets (Trailing 12 Months) | 2.50% |
| Current Ratio (Most Recent Fiscal Quarter) | 1.11 |
| Quick Ratio (Most Recent Fiscal Quarter) | 0.99 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 2.99 |
| Inventory Turnover (Trailing 12 Months) | 4.23 |
| Book Value per Share (Most Recent Fiscal Quarter) | $8.16 |
| Earnings per Share (Most Recent Fiscal Quarter) | $1.90 |
| Earnings per Share (Most Recent Fiscal Year) | $7.51 |
| Diluted Earnings per Share (Trailing 12 Months) | $-3.10 |
| Exchange | NYSE |
| Sector | Healthcare |
| Industry | Drug Manufacturers - General |
| Common Shares Outstanding | 2.03B |
| Free Float | 2.03B |
| Market Capitalization | $90.31B |
| Average Volume (Last 20 Days) | 14.45M |
| Beta (Past 60 Months) | 0.45 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 0.09% |
| Percentage Held By Institutions (Latest 13F Reports) | 76.41% |
| Annual Dividend (Based on Last Quarter) | $2.40 |
| Dividend Yield (Based on Last Quarter) | 5.39% |